Companies: 10,795·Total market cap: $144.5T
Novartis AG

Novartis AG

NOVN.SWSIXHealthcare● Active
$117.04
$-0.30(-0.26%)
Market Cap$223.3B
P/E Ratio
52W High$131
52W Low$91.2

Novartis AG (NOVN.SW) Revenue

Annual & quarterly revenue history · segment & region breakdown

NOVN.SW · revenue · updated Jun 9, 2026

Core revenue metrics

Novartis AG trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
75883 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Novartis AG SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
NOVN.SW revenue by year · NOVN.SW revenue history · NOVN.SW annual revenue data

Compare revenue vs peers

Drug Manufacturers - General

Compare NOVN.SW revenue against listed peers. Click any row to open that company's revenue tab.

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Novartis AG receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Novartis AG reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Novartis AG's 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

NOVN.SW revenue · 4 questions

NOVN.SW's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

NOVN.SW revenueNOVN.SW annual revenuewhat is NOVN.SW revenueNOVN.SW TTM revenue

Source: FMP · Novartis AG SEC filings · GAAP · Novartis AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026